Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.

Le Meur G, Stieger K, Smith AJ, Weber M, Deschamps JY, Nivard D, Mendes-Madeira A, Provost N, Péréon Y, Cherel Y, Ali RR, Hamel C, Moullier P, Rolling F.

Gene Ther. 2007 Feb;14(4):292-303. Epub 2006 Oct 5.

PMID:
17024105
2.

Recombinant AAV-mediated gene transfer to the retina: gene therapy perspectives.

Rolling F.

Gene Ther. 2004 Oct;11 Suppl 1:S26-32. Review.

PMID:
15454954
3.

AAV-mediated gene therapy for retinal disorders: from mouse to man.

Buch PK, Bainbridge JW, Ali RR.

Gene Ther. 2008 Jun;15(11):849-57. doi: 10.1038/gt.2008.66. Epub 2008 Apr 17. Review.

PMID:
18418417
4.

Gene therapy for vision loss -- recent developments.

Stieger K, Lorenz B.

Discov Med. 2010 Nov;10(54):425-33. Review.

5.

The consortium project to treat RPE65 deficiency in humans.

Hauswirth WW.

Retina. 2005 Dec;25(8 Suppl):S60. Review. No abstract available.

PMID:
16374340
6.

Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis.

Stein L, Roy K, Lei L, Kaushal S.

Expert Opin Biol Ther. 2011 Mar;11(3):429-39. doi: 10.1517/14712598.2011.557358. Review.

PMID:
21299439
7.

RPE65: role in the visual cycle, human retinal disease, and gene therapy.

Cai X, Conley SM, Naash MI.

Ophthalmic Genet. 2009 Jun;30(2):57-62. doi: 10.1080/13816810802626399. Review.

8.

Gene therapy for Leber congenital amaurosis.

Bennett J.

Novartis Found Symp. 2004;255:195-202; discussion 202-7. Review.

PMID:
14750605
9.

Function of the protein RPE65 in the visual cycle.

Wolf G.

Nutr Rev. 2005 Mar;63(3):97-100. Review.

PMID:
15825812
10.

Adeno-associated virus-vectored gene therapy for retinal disease.

Dinculescu A, Glushakova L, Min SH, Hauswirth WW.

Hum Gene Ther. 2005 Jun;16(6):649-63. Review.

PMID:
15960597
11.

Recombinant adeno-associated viral vectors in the nervous system.

Burger C, Nash K, Mandel RJ.

Hum Gene Ther. 2005 Jul;16(7):781-91. Review.

PMID:
16000060
12.

Manufacturing and regulatory strategies for clinical AAV2-hRPE65.

Wright JF, Wellman J, High KA.

Curr Gene Ther. 2010 Oct;10(5):341-9. Review.

PMID:
20712582
13.

Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients.

Colella P, Auricchio A.

Hum Gene Ther. 2012 Aug;23(8):796-807. doi: 10.1089/hum.2012.123. Review.

14.

Leber's congenital amaurosis and RPE65.

Harris EW.

Int Ophthalmol Clin. 2001 Winter;41(1):73-82. Review. No abstract available.

PMID:
11198148
15.

Viral vectors for targeting the canine retina: a review.

Petersen-Jones SM.

Vet Ophthalmol. 2012 Sep;15 Suppl 2:29-34. doi: 10.1111/j.1463-5224.2012.01054.x. Epub 2012 Aug 6. Review.

PMID:
22882429
16.

Ocular gene therapy: an evaluation of recombinant adeno-associated virus-mediated gene therapy interventions for the treatment of ocular disease.

Roy K, Stein L, Kaushal S.

Hum Gene Ther. 2010 Aug;21(8):915-27. doi: 10.1089/hum.2010.041. Review.

PMID:
20384478
17.

AAV-mediated gene transfer for retinal diseases.

Allocca M, Tessitore A, Cotugno G, Auricchio A.

Expert Opin Biol Ther. 2006 Dec;6(12):1279-94. Review.

PMID:
17223737
18.

Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies.

den Hollander AI, Black A, Bennett J, Cremers FP.

J Clin Invest. 2010 Sep;120(9):3042-53. doi: 10.1172/JCI42258. Epub 2010 Sep 1. Review. Erratum in: J Clin Invest. 2011 Jan 4;121(1):456-7.

19.

Promising and delivering gene therapies for vision loss.

Carvalho LS, Vandenberghe LH.

Vision Res. 2015 Jun;111(Pt B):124-33. doi: 10.1016/j.visres.2014.07.013. Epub 2014 Aug 2. Review.

20.

Immunology of AAV-Mediated Gene Transfer in the Eye.

Willett K, Bennett J.

Front Immunol. 2013 Aug 30;4:261. doi: 10.3389/fimmu.2013.00261. eCollection 2013. Review.

Supplemental Content

Support Center